| Dr James Michael Harrison, MD | |
|
676 Futenma, Fpo, AP 96379 | |
| (098) 971-9355 | |
| Not Available |
| Full Name | Dr James Michael Harrison |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 676 Futenma, Fpo, Armed Forces Pacific |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083031231 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 0101258659 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Michael Harrison, MD 620 John Paul Circle, Naval Medical Center Portsmouth, Portsmouth, VA 23708 Ph: (757) 953-3500 | Dr James Michael Harrison, MD 676 Futenma, Fpo, AP 96379 Ph: (098) 971-9355 |
News Archive
Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.
Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).
New research from Arizona State University, USA, uses a novel mathematical model to predict the impact of vaccination and vaccine-induced cross-protection on the B.1.1.7 variant and other SARS-CoV-2 variants circulating in the US as of June 2021. The study has been published in medRxiv* preprint server, while it undergoes peer review.
Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.
The AstraZeneca HealthCare Foundation program, Connections for Cardiovascular Health, today announced a grant of more than $186,000 to West Virginia Health Right, Inc. in Charleston to expand the Pathways to Cardiovascular Health program.
› Verified 8 days ago
Dr. Joshua Paul Garland, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-243-5868 | |
Dr. Thomas Kelsey, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: Psc 482, Fpo, AP 96362 Phone: 098-971-7351 | |
Carl A Nunziato, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3d Medical Battalion, Unit 38445, Fpo, AP 96373 Phone: 315-645-4197 | |
Dr. Frederic Sylvia, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Psc 482 Box 217, Fpo, AP 96362 Phone: 011-816-117437297 | |
Dr. Jason Howard Rockwood, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 046-816-7144 |